BioXcel Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Rule

FacebookFacebookTwitterTwitterEmailEmailLinkedInLinkedInWhatsAppWhatsAppMessengerMessengerFlipboardFlipboardGmailGmailTelegramTelegramShareShare

NEW HAVEN, Conn., Feb. 28, 2025 (GLOBE NEWSWIRE) — BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience, today announced that it has received written notice from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) that the Company has regained compliance with the minimum closing bid price requirement under Nasdaq Listing Rule 5550(a)(2).

As previously disclosed, on September 16, 2024, the Company was notified by Nasdaq that it was not in compliance with Nasdaq Listing Rule 5550(a)(2) because its common stock failed to maintain a minimum closing bid price of $1.00 per share for 30 consecutive business days. To regain compliance, the Company was required to maintain a minimum closing bid price of $1.00 per share for at least 12 consecutive trading days. This requirement was met on February 26, 2025.

About BioXcel Therapeutics, Inc.
BioXcel Therapeutics, Inc. (Nasdaq: BTAI) is a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience. Its wholly owned subsidiary, OnkosXcel Therapeutics, is focused on the development of medicines in immuno-oncology. The Company’s drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indications. For more information, please visit bioxceltherapeutics.com.

Contact Information

Corporate/Investors
BioXcel Therapeutics
Erik Kopp
1.203.494.7062

Media
Russo Partners
David Schull
1.858.717.2310

Source: BioXcel Therapeutics, Inc.

Staff

Recent Posts

Healthee Launches Smarter, Simpler, AI-Powered Benefits Platform

NEW YORK, June 25, 2025 /PRNewswire/ -- Healthee is proud to announce that the reimagined…

14 hours ago

Tobin Scientific Hires Graham Long as Chief Commercial Officer

Seasoned life sciences executive joins in key leadership role to support next phase of growth…

14 hours ago

Fortify Children’s Health Uses Oracle Health Data Intelligence to Enhance Pediatric Care Across Its Clinical Network

Virginia-based pediatric care network gains more complete picture of a child's health history, supports early…

14 hours ago

Elfie raises $12m to expand access to free digital therapeutics for all diseases

NEW YORK, June 25, 2025 /PRNewswire/ -- Elfie, the free digital health super-app that rewards people…

14 hours ago